phase readout

NCT05490771: Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)

ACTIVE_NOT_RECRUITINGupdated 1mo ago

community read0 votes

Sponsor: National Cancer Institute (NCI). Phase: PHASE2. Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma

view source ↗

NCT05490771: Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)

Report a data issue

comments(0)